Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
Esperion Therapeutics, wholly owned by ARCHIMED, is rolling out ENBUMYST, an intranasal bumetanide nasal spray for short-term treatment of edema in heart failure patients. This new administration route offers a non-invasive alternative to IV diuretics and aligns with upcoming CMS Ambulatory Specialty Model payment reforms starting 2027. Esperion ai…